Kyprolis revenue trends
In 1Q18, Amgen’s (AMGN) Kyprolis revenue grew 17% YoY (year-over-year) to $222 million from $190 million, primarily due to higher unit demand in international markets. It fell ~2% quarter-over-quarter.
During the quarter, Kyprolis generated US and international revenue of $137 million and $85 million, respectively. Its US revenue was flat YoY. Kyprolis maintained a stable US market share in the second-line setting.
In April, the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the label expansion of Kyprolis based on the final OS (overall survival) data from its Phase 3 ASPIRE trial, where Kyprolis, lenalidomide, and dexamethasone combination therapy demonstrated a 21% reduction in risk of death compared with lenalidomide and dexamethasone therapy. Relapsed and refractory multiple myeloma patients receiving Kyprolis, lenalidomide, and dexamethasone combination therapy showed a median OS of 48.3 months, while patients receiving just lenalidomide and dexamethasone showed a median OS of 40.4 months.
The label expansion of Kyprolis is expected to strengthen its commercialization. Kyprolis was first approved in 2012, and since then, ~80,000 patients have received Kyprolis therapy. In the multiple myeloma drug market, Kyprolis’s peers include Takeda’s (TKPYY) Velcade and Ninlaro, Celgene’s (CELG) Pomalyst and Thalomid, and Novartis’s (NVS) Zometa.